DMPK/ADME for Ovarian Cancer Drugs

DMPK (drug metabolism and pharmacokinetics) and ADME (absorption, distribution, metabolism, and excretion) are essential in ovarian cancer drug development. Alfa Cytology specializes in studying DMPK and ADME for ovarian cancer drugs, focusing on drug metabolism and the bioactivity of their metabolites.

Introduction to DMPK/ADME

DMPK and ADME studies are crucial for developing ovarian cancer drugs, helping scientists understand their behavior and effects in the body. Absorption properties determine how efficiently a drug enters the bloodstream, while distribution properties affect its concentration in tumor tissues, critical for efficacy. Metabolic studies reveal how drugs are transformed by enzymes, ensuring both safety and effectiveness. Lastly, excretion studies determine the rate at which drugs and their metabolites are cleared, affecting the drug's half-life and dosing frequency.

Fig.1 Current trends in drug metabolism and pharmacokinetics. (LI Y, et al, 2019)

Factors Influencing ADME/DMPK

Compound Characterization

The chemical structure and solubility of a compound critically influence its absorption and bioavailability within the body.

Route of Administration

The mode of administration-whether oral, intravenous, subcutaneous, or otherwise-significantly impacts the rate and extent of drug absorption.

Physiological Factors

Variations in age, gender, genetic makeup, and health status can lead to differences in how drugs are metabolized and excreted by individuals.

Biological Membrane Permeability

The configuration of cell membranes plays a pivotal role in determining how effectively a drug can penetrate and reach its target tissue.

Our Services

Alfa Cytology, equipped with a highly skilled scientific team, specializes in DMPK/ADME studies for ovarian cancer drugs. By employing rigorous experimental designs and advanced analytical techniques, Alfa Cytology is committed to optimizing drug efficacy and safety, thereby enhancing ovarian cancer treatment.

In Vitro ADME for Cancer Therapy

Providing in vitro ADME studies to analyze the absorption, distribution, metabolism, and excretion properties of ovarian cancer therapeutics in cells.

In Vivo PK for Cancer Therapy

Offering crucial insights into a drug's behavior in the body, including its absorption and distribution to the tumor site, through in vivo PK studies.

Assays for DMPK/ADME

DMPK and ADME assays encompass a range of experiments designed to provide an in-depth understanding of drug behavior within the body. These studies evaluate how well drugs are absorbed, distributed, metabolized, and excreted, helping researchers ensure efficacy and safety in ovarian cancer treatment.

Absorption: Assessing drug entry into blood circulation using methods like the Caco-2 cell permeability test.
Distribution: Analyzing drug distribution across tissues and organs through plasma protein binding assays and tissue distribution studies.
Pharmacokinetic (PK) Studies: Analyzing drug absorption, distribution, metabolism, and excretion through plasma concentration profiles.
Bioavailability Studies: Assessing the proportion of a drug effectively utilized post-administration by comparing oral and intravenous effects.

Alfa Cytology is committed to advancing drug development for ovarian cancer through extensive DMPK and ADME studies. By deeply analyzing these critical factors, we aim to enhance the bioavailability and safety of therapeutic drugs. Please contact us for any inquiries about our related services.

Reference

LI Y, MENG Q, YANG M, et al. Current trends in drug metabolism and pharmacokinetics [J]. Acta Pharm Sin B, 2019, 9(6): 1113-44.

! For research use only.